Vir Biotechnology appoints David Liu as chief medical officer to steer hepatitis D phase 3 and cancer programs

Vir Biotechnology announced the appointment of David Liu, M.D., Ph.D., as its new chief medical officer.

Liu comes from a recent stint as CMO at Nuvation Bio and has held senior roles at AstraZeneca, Bristol Myers Squibb and Celgene, giving him deep drug development expertise.

In his new role he will oversee the phase 3 trial of Vir’s lead hepatitis D combination therapy and help advance the company’s early‑stage cancer pipeline, drawing on his immuno‑oncology background.